Lutetium-(177Lu)-vipivotide-tetraxetan: Nephrotoxicity.
In: Reactions Weekly, Jg. 1995 (2024-02-17), Heft 1, S. 109-109
serialPeriodical
Zugriff:
In a retrospective cohort study, two men with metastatic castration-resistant prostate cancer (mCRPC) developed nephrotoxicity during treatment with lutetium-(177Lu)-vipivotide-tetraxetan. The patients had a medical history of hypertension and mCRPC and received multiple cycles of IV lutetium-(177Lu)-vipivotide-tetraxetan. One year after treatment initiation, one patient experienced a significant decrease in estimated glomerular filtration rate (eGFR), while the other patient also exhibited a decline in eGFR. Nephrotoxicity caused by lutetium-(177Lu)-vipivotide-tetraxetan was confirmed in both patients. [Extracted from the article]
Titel: |
Lutetium-(177Lu)-vipivotide-tetraxetan: Nephrotoxicity.
|
---|---|
Zeitschrift: | Reactions Weekly, Jg. 1995 (2024-02-17), Heft 1, S. 109-109 |
Veröffentlichung: | 2024 |
Medientyp: | serialPeriodical |
ISSN: | 0114-9954 (print) |
DOI: | 10.1007/s40278-024-53372-4 |
Schlagwort: |
|
Sonstiges: |
|